Home Newsfeeds BrainStorm Cell Therapeutics Presents NurOwn Phase 2 Progressive MS Biomarker Data at the 38th ECTRIMS Congress

BrainStorm Cell Therapeutics Presents NurOwn Phase 2 Progressive MS Biomarker Data at the 38th ECTRIMS Congress

BrainStorm Cell Therapeutics Inc.

byCharles Gross

October 20, 2022

1 minute read

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that a scientific abstract titled ‘NurOwn (MSC-NTF) Phase 2 Clinical Trial in Progressive MS: Effects on CSF Neuroprotective Biomarkers’ will be presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held from October 26-28th in Amsterdam, NL.

Vintage Wine Estates Provides Business Update And Preliminary Outlook For FY24; Sees FY24 Revenue $290M Vs $270.93M Est

By Happy Mohamed

July 20, 4:29 PM

Preliminary unaudited fiscal 2023 revenue is estimated to be $290 million with gross margin of approximately 30% to 32% Announces preliminary expectations for fiscal 2024 reflecting

VWE

REV Group, Inc. Announces Proposed Secondary Offering Of 12M Shares Of Common Stock And Concurrent Share Repurchase

By Benzinga Newsdesk

February 13, 5:40 PM

REV Group, Inc. (NYSE:REVG) announced today the commencement of an underwritten public offering of 12,000,000 shares of common stock by certain selling stockholders. In connection with the offering, the selling

REVG

Truist Securities Maintains Buy on AAR, Lowers Price Target to $48

By Benzinga Newsdesk

September 23, 9:36 AM

Truist Securities analyst Michael Ciarmoli maintains AAR (NYSE:AIR) with a Buy and lowers the price target from $54 to $48.

AIR

News

Biophytis Plans To File IND With FDA For Phase 2 OBA Clinical Study In Obesity, Backed By New Scientific Advisory Board

By Benzinga Newsdesk

April 18, 3:01 AM

IND to be filed with the FDA in the coming weeks PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 18, 2024 / Biophytis SA (NASDAQ:BPTS)(PARIS:ALBPS), ("Biophytis" or the "Company"), a

BPTS

BrainStorm Cell Therapeutics Presents NurOwn Phase 2 Progressive MS Biomarker Data at the 38th ECTRIMS Congress

Related Posts

Vintage Wine Estates Provides Business Update And Preliminary Outlook For FY24; Sees FY24 Revenue $290M Vs $270.93M Est

REV Group, Inc. Announces Proposed Secondary Offering Of 12M Shares Of Common Stock And Concurrent Share Repurchase

Truist Securities Maintains Buy on AAR, Lowers Price Target to $48

Biophytis Plans To File IND With FDA For Phase 2 OBA Clinical Study In Obesity, Backed By New Scientific Advisory Board